All News
Prevotella Immune Response in Both Pre-Clinical & Established RA
d
EurekAlert! and Jack Cush
In a recent analysis published in Arthritis & Rheumatology, people at risk for rheumatoid arthritis (RA) and those with the disease had elevated blood levels of antibodies against a Prevotella copri (Pc).
Read Article
Miners Face Increased Risk of Rheumatoid Arthritis
d
MedPage Today
Add "hard rock" mining to the list of occupations associated with high rates of rheumatoid arthritis (RA), a new study indicated, with silica exposure the presumed malefactor.
Read Article
CRTAC1- a Novel Biomarker for Osteoarthritis
d
EurekAlert!
Scientists at deCODE genetics a subsidiary of Amgen report in Arthritis & Rheumatology that a novel plasma protein (cartilage acidic protein-1; CRTAC1) is a potential biomarker of osteoarthritis (OA) through its association with OA risk and progression to joint replacement.
Read Article
Dr. Kent Kwoh and Researchers at the University of Arizona Arthritis Center have been awarded a $3.4 million grant from the National Institutes of Health to undertake a study that seeks to identify determinants of rapid knee deterioration in OA https://t.co/EodUXk6FDp https://t.co/bX2k5c7lR9
Links:
Dr. John Cush RheumNow ( View Tweet)
NEJM: Dysphagia Due to Diffuse Idiopathic Skeletal Hyperostosis - 70yoM with 6-month history of dysphagia. Compression of the hypopharyx by large cervical osteophytes was seen in a videofluoroscopic swallowing study https://t.co/AVDXPzhfjd https://t.co/7TwY0CGaxb
Links:
Dr. John Cush RheumNow ( View Tweet)
Cross-sectional study of 291 PCPs shows that increased electronic health record (EHR) time was associated with a significantly greater liklihood of meeting patient target goals for Hgb-A1C, HTN control and breast cancer screening https://t.co/mLdoHM9N7O https://t.co/li6QD5jq7F
Links:
Dr. John Cush RheumNow ( View Tweet)
Arthritis Clinical Trials Comparison Grid
Use this resource to keep track of your clinical trials and key information needed when communicating with patients about a drug study.
https://t.co/9z42zfr1Fx https://t.co/dYAjOVvTaW
Links:
Dr. John Cush RheumNow ( View Tweet)
EMA CHMP issued a positive opinion on the safety of Filgotinib, a selective JAK1 inhibitor, based on testicular safety data from the MANTA & MANTA-RAy studies. Gilead withdrew filgotinib from US market w/ FDA concerns on testicular safety in 12/20 https://t.co/38xOWb1zJi https://t.co/jPUy6H1QQN
Links:
Dr. John Cush RheumNow ( View Tweet)
Urine proteomics on 54 SLE pts in the Belimumab–Lupus Nephritis trial, compared responders (n 31) v non-responders (n 22), on BEL or SOC. Reduction in urinary CD163 was strongly associated with complete renal response @wk52 & CD23 @wk24 https://t.co/PrXaJq6h0E https://t.co/IWREF9VmZ8
Links:
Dr. John Cush RheumNow ( View Tweet)
A Review of AOSD - Adult - Onset Still's Disease
https://t.co/VvWX5t3WPY
@Stills_Now https://t.co/uEoCjhViRP
Links:
Dr. John Cush RheumNow ( View Tweet)
In this week's special podcast, Dr. Jack Cush offers a primer on rheumatology clinical trials, answering the question: should you be involved in research and clinical trials in rheumatology?
https://t.co/yuCAmwsoAY https://t.co/vC835UUxzI
Links:
Dr. John Cush RheumNow ( View Tweet)
Do you renal Bx your #SLE pts? Study of 277 SLE pts w/ US-guided percutaneous renal bx showed bleeding complications post biopsy to be 19.9% (minor 13%; major 7%); risk higher w/ thrombocytopenia (OR 7.12)low eGFR (OR 3.5) https://t.co/vYYChuGdSN https://t.co/kULTEnNYC9
Links:
Dr. John Cush RheumNow ( View Tweet)
NEJM: 70 yoWM w/ 3-wk temporal headaches, jaw pain with chewing, temporal artery tender and thickened, but NO vision Sxs. a 15, CRP 24 mg/L. and Doppler US showed “halo sign” . Temp art Bx confirmed the Dx of GCA https://t.co/ayPcVKctEA https://t.co/g3iP0Akbzs
Links:
Dr. John Cush RheumNow ( View Tweet)
Co-administration of MTX with Folic Acid on the same day did not reduce efficacy compared to FA application one day after MTX. (based on AIA was induced in female Lewis rats) https://t.co/WBT5BOBPqz https://t.co/bP6O24kgXy
Links:
Dr. John Cush RheumNow ( View Tweet)
No Special Heart Risk With JAK Inhibitors, Study Finds
Patients taking JAK inhibitors for RA experienced similar cardiovascular outcomes as those using the TNF blocker adalimumab (Humira), analysis of French national registry data indicated.
https://t.co/Ai3xTPcoO8 https://t.co/TuMaQMWepj
Links:
Dr. John Cush RheumNow ( View Tweet)
Arthritis Clinical Trials Comparison Grid
https://t.co/BEvMKU1WEE https://t.co/2TpxMbWE7h
Links:
Dr. John Cush RheumNow ( View Tweet)
An incredible opportunity for a free Rheumatology Review course hosted by the Pakistan Rheumatology Society
-Event is virtual and registration is free
-Course starts tomorrow 10/16 at 1:30 PM Pakistan time (5:30 AM ET)
See below for details👇🏼👇🏼👇🏼 https://t.co/tHeFwRZHcG
Dr. Laura Lewandowski LauraLewMad11 ( View Tweet)
Sjogrens - Dx tips, myths & mistakes:
• SS not rare; affects 1 in 400
• 95% female, but SS is more severe in men
• African Americans have a severe systemic phenotype
• Asians report dryness Sxs
• Smoking & alcohol intake often avoided by SS pts
https://t.co/f4C0eYv9Ee https://t.co/OOEXfH6jQs
Links:
Dr. John Cush RheumNow ( View Tweet)
Biomedical researchers are at their most creative/innovative EARLY in their career. Study based on 5.6 million papers (1980 to 2009). While least innovative drop out early; in the remaining, innovativeness tends to decline over their career.https://t.co/jXxkEKnl8o https://t.co/mGPokRjkaP
Links:
Dr. John Cush RheumNow ( View Tweet)
Intravenous Immune Globulin in Dermatomyositis
Few drugs have been studied well in the treatment of dermatomyositis (DM) and only recently has intravenous immune globulin (IVIG) been granted FDA approval for the treatment of DM, based on this trial.
https://t.co/8QeEzX8Eqm https://t.co/hUVLUQJjN6
Links:
Dr. John Cush RheumNow ( View Tweet)
